By analyzing whole-exome sequencing results from an advanced prostate cancer patient cohort, we explored potentially activating alterations in the PI3K pathway and identified oncogenic alterations across the dominant drivers of PI3K signaling (PTEN, PIK3CA, PIK3CB, PIK3R1) (Fig. 1a). Here, PIK3CD is linked to prostate cancer.